Search Results 8891-8900 of 42492 for oral

  1. A Study to Evaluate the Safety and Effectiveness of Etrasimod in Adults with Eosinophilic Esophagitis - Mayo Clinic

    Used any immunotherapy/desensitization including oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) within 12 months prior to the Screening EGD ...

  2. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer - Mayo Clinic

    ... oral investigational agents Unwilling or unable to, comply with the protocol. Any of the following prior therapies: Radiation to ≥ 25% of bone marrow; Major ...

  3. A Study Of Niraparib Maintenance Treatment In Patients With Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy - Mayo Clinic

    Patients must be able to take oral medications. Exclusion Criteria: Patient has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma ...

  4. Sleep disorders - Doctors and departments - Mayo Clinic

    ning mouth syndrome, Oral lichen planus, Skin cancer, Skin problems, Dermatitis, Hair loss, Morphea, Canker sores, Klippel-Trenaunay syndrome, Psoriasis ...

  5. Hematology - Clinical trials

    ... oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) ...

  6. Hematology - Clinical trials

    ... oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) ...

  7. Parotid tumors - Doctors and departments - Mayo Clinic

    vascular surgery, Parotidectomy, Transoral laser microsurgery, Throat cancer, Oral and throat cancer, Mouth cancer, Thyroid cancer, Head and neck cancer ...

  8. A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    ... oral contraceptives; (2) tyrosine kinase inhibitors (TKIs) that have been discontinued greater than (>) 7 days prior to Cycle 1, Day 1, baseline scans must ...

  9. A Study To Evaluate AZD1775 In Women With Recurrent Or Persistent Uterine Serous Carcinoma Or Uterine Carcinosarcoma - Mayo Clinic

    Participants must be able to swallow oral medication and may not have a percutaneous endoscopic gastrostomy (PEG) tube, be receiving total parenteral ...

  10. A Study of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment for Patients with Stage IIIB/IV Non-Small Cell Lung Cancer - Mayo Clinic

    Has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of ...